Background-Cardiac resynchronization therapy (CRT) can improve ventricular size, shape, and mass and reduce mitral regurgitation by reverse remodeling of the failing ventricle. About 30% of patients do not respond to this therapy for unknown reasons. In this study, we aimed at the identification and classification of CRT responder by the use of genetic variants and clinical parameters. Methods and Results-Of 1421 CRT patients, 207 subjects were consecutively selected, and CRT responder and nonresponder were matched for their baseline parameters before CRT. Treatment success of CRT was defined as a decrease in left ventricular end-systolic volume >15% at follow-up echocardiography compared with left ventricular end-systolic volume at baseline. All other changes classified the patient as CRT nonresponder. A genetic association study was performed, which identified 4 genetic variants to be associated with the CRT responder phenotype at the allelic (P<0.035) and genotypic (P<0.031) level: rs3766031 (ATPIB1), rs5443 (GNB3), rs5522 (NR3C2), and rs7325635 (TNFSF11). Machine learning algorithms were used for the classification of CRT patients into responder and nonresponder status, including combinations of the identified genetic variants and clinical parameters. Conclusions-We demonstrated that rule induction algorithms can successfully be applied for the classification of heart failure patients in CRT responder and nonresponder status using clinical and genetic parameters. Our analysis included information on alleles and genotypes of 4 genetic loci, rs3766031 (ATPIB1), rs5443 (GNB3), rs5522 (NR3C2), and rs7325635 (TNFSF11), pathophysiologically associated with remodeling of the failing ventricle.
T he concept of individually optimized therapy, often referred to as personalized medicine, is rapidly advancing in the field of modern healthcare, 1 in particular for common diseases. Personalized medicine is expected to improve the treatment of cardiovascular disease (CVD), including prognosis of treatment outcomes. 2 As a novel integrative approach, personalized medicine in the treatment of CVD will have to collect and selectively evaluate a patient's unique clinical and anthropometric parameters, as well as information on genetic predisposition. It is well-known that CVD is a highly heritable trait, 3 with individual combinations of multiple genetic variants accounting for different CVD phenotypes 4 in combination with classic risk factors. Classic risk factors alone explain a large proportion (>50%) of CVD risk, whereas an estimated 15% to 20% of myocardial infarction patients have none of the traditional risk factors. 5, 6 Increased knowledge of the molecular mechanisms involved and insight into the additive and interactive effects of multiple genetic variants and environmental factors have been postulated as the foundation for novel therapeutic strategies. 7 Even at the current state of knowledge, genetic information allows clinicians to stratify individuals who are at intermediate risk by generation of clinically useful treatment recommendations if interpreted correctly. 7 We have most recently developed a data mining approach including rule-based machine learning algorithms for the classification of CVD patients and the extraction of potential risk predictors including genetic variants. 8 In the current study, we have applied this methodology on top of a genetic association study to extract potential combinations of genetic variants and clinical parameters as markers for treatment success in patients with chronic systolic heart failure (HF) treated by cardiac resynchronization therapy (CRT).
CRT combines right atrial and ventricular pacing with pacing of the left ventricular (LV) free wall by a third lead, introduced through the coronary sinus in the great cardiac vein to resynchronize contraction between and within ventricles. CRT has been shown to ameliorate ventricular size, shape, and pump function and reduce mitral regurgitation by reverse remodeling (RR) of dilated failing ventricles and to improve survival in patients with moderate to severe HF and intraventricular conduction delay. 9 However, it is estimated that over one third of patients do not respond to this therapy. 10 Many criteria to define a positive response to CRT have been used with a wide variability between studies. 11, 12 Proposed measures include (1) primary clinical end points such as mortality because of progressive pump dysfunction or CV events and cardiac transplantation; (2) secondary clinical end points such as rehospitalization for worsening HF; and (3) subjective or objective changes in functional capacity expressed as improved New York Heart Association (NYHA) class or the increase in the distance walked in 6 minutes, respectively, 3 to 6 months after CRT implantation. Echocardiographic criteria include changes observed 3 to 6 months after the procedure in left ventricular ejection fraction (LVEF) or left ventricular end-systolic (LVESV) or end-diastolic (LVEDV) volume, using different cutoff values. RR has been shown to start early after CRT, to peak between 6 and 12 months and to be sustained in the long-term, ≤5 years, with only little further improvement. 13, 14 Agreement between clinical and echocardiographic criteria has been shown to be modest at best. 11 In general, the rate of response using clinical criteria is higher compared with the rate of response when remodeling markers are considered but clinical measures of response are poorly correlated to longterm prognosis. Conversely, death from CV causes or progressive pump failure has been shown to be dependent on RR, and changes in LVESV are acknowledged as a reliable surrogate end point. RR and CV mortality seem to correlate in the medium-term, and the relationship is sustained ≤5 years. [15] [16] [17] Predictors of CRT success have been extensively investigated and include female sex, nonischemic pathogenesis of HF, symptom severity, myocardial scar burden, QRS morphology and duration, and technical factors such as LV lead placement or proportion of time paced. 10, [18] [19] [20] [21] Whether genetic variants associated with CVD may be differentially associated with CRT success has been hitherto poorly investigated. Our approach aimed at more specifically classifying CRT responders by inclusion of predictive genetic markers within a study of CRT patients recently published by our group.
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Methods
Study Design and Patient Selection
The CRT study for identification of predictive genetic markers was a retrospective multicenter case-control study conducted at 3 Italian centers. 22 The study was approved by the institutional ethics committees of the participating centers, and patients expressed their written informed consent to participate. The study included HF patients who had undergone CRT to correct mechanical dyssynchrony represented by a sequence abnormality in atrioventricular, or inter-or intraventricular contraction according to guideline indications: any pathogenesis of HF, NYHA classification II-IV, a QRS duration on surface ECG of ≥120 ms, LVEF ≤35%, and LV end-diastolic diameter >55 mm. 23 Assessment of scar burden was performed before patient selection for the procedure; patients with extensive scar burden were excluded from CRT. Further study entry criteria were stable positioning of the left lead at the lateral or posterolateral wall level and proportion of time paced >97%. In patients with atrial fibrillation, atrioventricular node ablation was performed to achieve this percent pacing target, and atrioventricular delay was optimized under echocardiographic guidance immediately postimplant.
Of 1421 patients (18% deceased), implanted with CRT since 2002, the study enrolled 207 consenting subjects who had undergone the procedure since at least 6 to 12 months, had a valid echocardiographic study to define the remodeling status at 6 to 12 months (median 9 months), and were consecutively reviewed in the electrophysiology outpatient clinic for routine follow-up between March and December 2009 (Figure 1 ).
Definition of Treatment Success
CRT treatment success, designated as reverse remodeling (RR+), was defined as a significant decrease in LVESV >15% (ie, a reduction in LV size) at follow-up compared with LVESV at baseline determined by echocardiography. All other changes classified the patient as CRT nonresponder (RR−). For each RR+ patient, a RR− subject was enrolled matched by sex, age, NYHA functional class, HF pathogenesis, and baseline LVEF.
Echocardiography
LVESV was measured by transthoracic echocardiography examinations at rest using conventional methods with commercially available ultrasound devices (Sonos 7500 and IE33, Philips Medical Systems, Andover, USA; Sequoia C256 Acuson, Siemens, Mountain View, USA; Famiglia Mylab25, Esaote, Genoa, Italy; Vivid System 7, GE/ Vingmed, Milwaukee, USA) equipped with a 2.5-to 3.5-MHz phased array sector scan probe. Parameters were obtained by 2-and 4-chamber view using the biplane discs' summation method (Simpson rule).
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Genotyping
Patients' blood was sampled during a follow-up outpatient visit. Genomic DNA was extracted at the University Hospital of Münster. Genotyping was performed, blinded to patients' remodeling status, using TaqMan SNP genotyping assays on the real-time PCR System ABI7900 (Life Technologies Corporation, Carlsbad, USA) in a 384-well format. For detailed PCR conditions, see information in the online-only Data Supplement. Replicate samples and samples without template were used as controls. Genotyping call rates were >95%.
Hardy-Weinberg equilibrium was tested by calculating the expected genotype frequencies from the allele frequencies. Deviation from the observed genotype frequencies was determined by χ 2 test. Genotype distributions of the 6 analyzed genes were compatible with HardyWeinberg equilibrium, except for rs5723 within SCNN1G.
Selection of Genes and Genetic Variants
With respect to the selection of appropriate genetic variants, we conducted a literature search including different combinations of the terms: genetic variant, single nucleotide polymorphism, CVD, and vascular remodel(l)ing (http://www.ncbi.nlm.nih.gov/pubmed; last date of access 28.02.2010). The main focus of the search was on variants for which functional data were available. The results were evaluated for appropriate and reasonable quality of the report and reproducibility. Because of the smaller sample size of our study group, genetic variants with a reported minor allele frequency <10% in white population have not been included. Data on gene regulation from our own laboratory have also been taken into account. 25 The final set of genetic variants tested included the common GNB3 (guanine nucleotide-binding beta polypeptide 3 [Gβ3]) rs5443 T allele, which results in a truncated Gβ3 splice transcript leading to enhanced signal transduction, 26 enhanced activity of atrial inward rectifier potassium currents, 27 and increased response to vasoactive hormones. 28 ATP1B1 encodes the Na + /K + -ATPase β-subunit, an oligomeric membranebound protein essential for maintenance of the myocardial resting membrane potential. 29 Total Na + /K + -ATPase concentration has been reported to be decreased by 40% in endomyocardial biopsies from patients with compromised cardiac function. 30 The ATP1B1 locus has repeatedly been associated with CVD.
31 TNFSF11 encodes the osteoprotegerin ligand (receptor activator of nuclear factor κ-B ligand). Enhanced myocardial expression of the osteoprotegerin/receptor activator of nuclear factor κ-B ligand/RANK axis has been reported to contribute to LV remodeling, 32 whereas circulating osteoprotegerin levels have been suggested as independent predictors for CV mortality. 33, 34 The analysis also included NR3C2 rs5522, which has been shown previously to be associated with successful CRT. 23 In addition, genetic variants of the epithelial sodium channel α/γ (SCNN1A [rs3759324], SCNN1G [rs5723]) have been tested because epithelial sodium channel has been suggested as a mediator of aldosterone in the vascular endothelium. 35 
Statistical Analysis
Variables are presented as number (frequency percentage) or median [interquartile range]. Chi-square test for categorical variables and Student t test or Mann-Whitney test for continuous variables were used to compare the baseline characteristics of both groups. Relative allele and genotype frequencies were compared by χ 2 test (Fisher exact test, where appropriate). Recessive/dominant associations were tested by comparing allele and genotype frequencies between RR− and RR+ groups using contingency table and χ 2 or Fisher exact test. Given the group sample sizes of 80 RR+ and 76 RR− patients, the power to detect differences in allele frequencies of 0.16 for an allele of 34% frequency exceeded 80%. P values <0.05 were considered statistically significant. To correct for multiple comparison, we used the Benjamini and Yekutieli 36 false discovery rate method: statistical significance was declared at P≤0.014 using the formula p = a/Σ(1/i), where a = 0.05, i ranges from 1 to N, and N represents the number of comparisons including clinical and genetic variables (N=20). The associations between RR+ and genetic variants were assessed by multivariable logistic regression, after adjustment for clinically relevant potential confounders. The incremental predictive performance for RR+ of the predicted probability risk was determined by C statistic for (1) clinical variables and (2) the combination of clinical variables and genetic variants. The areas under the receiver operating characteristic curve with their 95% confidence interval (CI) were determined and compared by the method of DeLong et al. 37 The Statistical Package for the Social Sciences (SPSS) v 17 was used.
Data Mining and Machine Learning
Patients were grouped in the 2 categories RR+ and RR−. After data adjustment for simultaneous analysis of heterogeneous data sets, 5 independent classifiers (Table I in the online-only Data Supplement) including either patients' clinical (n=207; RR+=107, RR−=100; Table II in the online-only Data Supplement) or genetic information (n=156) or a combination of both (n=156) were subjected to a multitude of 15 machine learning algorithms (Methods in the online-only Data Supplement; Table III in the online-only Data Supplement). For each classifier, we used the 10-fold cross-validation approach to evaluate the general accuracy of the algorithm. Data were randomly partitioned into 10 separate sets, and each algorithm was provided with 9 of the sets as training data, while the remaining set was used as test cases. The process was repeated 10 times using the different possible test sets. The resulting accuracies were averaged. For the Decision Table and Voting Feature Intervals algorithm, the Leave One Out cross-validation method was used. For this method, the data set containing N observations is split into 2 subsets. One containing N-1 observations, which is used as the training set and another containing 1 observation, which is used for validation. The process is repeated in all possible ways until all observations have been used for validation. Random Forest, C4.5, PART, Decision Table, Bayes Network, and Multilayer Perceptron that proved to be the most reliable (ie, not overtrained) and accurate algorithms after the initial testing were further analyzed; they were applied several times, with different values for the parameters to identify the most efficient configuration in terms of specificity, sensitivity, and accuracy for the detection of RR+ and RR− individuals (Tables IV-VIII in the online-only Data Supplement).
PART is a blend of C4.5 38 and RIPPER. 39 Both methods adopt a 2-stage approach: a set of rules is produced and subsequently refined by omission (C4.5) or adjustment (RIPPER). As C4.5, PART generates rules from decision trees and uses the divide and conquer rule learning method as RIPPER, while inferring rules by repetitive generation of partial decision trees. Initially, a rule is produced, then the covered instances are removed and PART continuous building rules recursively for the residual instances until none is left. As the name suggests, PART generates partial decision trees with branches to undefined subtrees instead of fully explored trees, integrating building and pruning stages to identify a stable subtree that cannot be further cut down. When this subtree has been created, tree building ceases and a single rule is produced. For missing values, PART adopts the approach of C4.5: in case an instance cannot be assigned deterministically to a branch because of a missing attribute value, it is assigned to each of the branches with a weight proportional to the number of training instances going down that branch, normalized by the total number of training instances with known values at the node.
Results
Study Population
The characteristics of the HF patient study population before CRT is shown in Table 1 . All patients experienced severe pump dysfunction and advanced symptoms. The RR status with CRT at follow-up was determined after a median of 9 [7] [8] [9] [10] [11] [12] months. No significant differences existed in the clinical variables used for matching (age, atrial fibrillation, NYHA class, LVEF, and LVESV) between the patients analyzed and those not included in the study (Figure 1 ). RR− and RR+ group included 76 and 80 patients, respectively. Consistent with clinical matching, baseline parameters and medication were similar between groups, except for a slightly higher prevalence of type 2 diabetes mellitus (P=0.057). Significant differences, resulting from the defined remodeling phenotypes, were found between RR+ and RR− subjects for volume (P<0.001) and function (P<0.001) changes (Figure 2) . In RR+ patients, LVEDV decreased by 22 mL [−37 to −16 mL] 
Genetic Association Study
Information on genetic variants was available for 156 CRT study participants. Of 6 previously established genetic variants that had been associated with CVD phenotypes, 4 were associated with the RR+ phenotype (Table 2) at the allelic (P<0.035) and genotypic (P<0.031) level: rs3766031 (ATPIB1), rs5443 (GNB3), rs5522 (NR3C2), and rs7325635 (TNFSF11). Identified associations remained significant after correction for multiple testing by the Benjamini and Yekutieli false discovery rate method 36 (P≤0.014) for rs3766031 (ATPIB1), rs5443 (GNB3), and rs5522 (NR3C2).
By multivariable logistic regression analysis after adjustment for age, sex, LVEF, atrial fibrillation, NYHA class, type 2 diabetes mellitus, baseline LVEDV, and pathogenesis of HF, GNB3, ATP1B1, and NR3C2 remained independently associated with RR+ ( 
Data Mining and Machine Learning
When comparing specificity, sensitivity, and accuracy of the different algorithms applied within each classifier, we observed that some algorithms performed generally better than others (Table 4) . Approximation of 100% accuracy (based on the 10-fold cross-validation method) as detected for K Nearest Neighbors, Non-Nested Generalised Exemplars, and Random Tree in some classifiers indicated artificial overtraining of the applied method. Within the classifiers Clinical & Genotypes and Clinical & Alleles, the rule-based methods C4.5 and PART performed well, exceeding 82.5% accuracy. Because rule-based methods produce lower complexity classification results with higher transparency, which may be used to generate expert consensus in a modified Delphi method, 40 we identified the PART algorithm 41 as appropriate for the generation of efficient and interpretable rules (Table 5 ) in this series.
Discussion
In the current study, we demonstrated that machine learning algorithms can successfully be applied for the classification of HF patients treated with CRT into responders and nonresponders using clinical and genetic parameters to model prediction of RR. Our analysis included information on alleles and genotypes newly associated with the CRT responder phenotype. 
Markers and Determinants of CRT Response
Predicting whether a patient will benefit from CRT has long been an issue of interest, and surrogate end points of response at midterm follow-up have been used repeatedly. 12, 13, 18 The correlation between primary clinical measures of response, such as cardiac death, and symptomatic improvement has been observed to be poor, whereas RR after CRT strongly correlates with clinical outcome. [16] [17] [18] Consistently, as marker of CRT success, we used echocardiographic RR after a median follow-up of 9 months, a time interval coincident with peak changes in trials with repeated echocardiographic assessments. 13 We selected a well-balanced data set of RR+ and RR− patients matched for known clinical parameters that have been associated with a different incidence of RR after CRT such as ischemic pathogenesis of HF, lower LVEF, atrial fibrillation, shorter QRS duration, and female sex. [18] [19] [20] [21] As extensive myocardial scarring and procedural factors, including LV lead position and percent pacing, are important technical determinants of CRT success, 17, 20, 42, 43 a limited scar burden and technical success were prerequisites for enrollment in the study. Furthermore, postimplant atrioventricular delay optimization, which also impacts on response, 44 was routinely performed. However, we observed significant differences in patients' outcome, potentially based on unknown interactions of clinical parameters such as type 2 diabetes mellitus 45 and undetected genetic predispositions.
Data Mining Approach
Machine learning algorithms have already been used to model the pathobiology of complex CVD such as ischemic heart disease, 46 based on the combination of classic risk factors and genotype information. This approach has mainly been used in large population data sets to identify subpopulations of individuals at increased risk for the analyzed trait. 46, 47 A genetic profile in a disease model may be superior to a single measurement of risk factors if the included functional variants lead to a lifetime exposure to the affected condition. 48 After the assumption that CV risk factors have diverse and interdependent effects in individuals with a plurality of unknown parameters and variables, we applied 15 different machine learning algorithms to data sets of HF patients treated with CRT to discriminate RR− from RR+ individuals and included combinations of phenotypic risk factors and genetic information. We identified the PART algorithm as appropriate for the generation of efficient and interpretable rules in this series. Values are expressed as n (frequency percent). P values for categorical variables were calculated by χ 2 or Fisher exact test. ATP1B1 indicates sodium/potassium-transporting ATPase subunit β-1; GNB3, guanine nucleotide-binding protein (G protein), β polypeptide 3; NR3C2, mineralocorticoid receptor; RR, reverse remodeling; SCNN1A, epithelial sodium channel α-subunit; SCNN1G, epithelial sodium channel gamma subunit; TNFSF11, tumor necrosis factor (ligand) superfamily, member 11 (RANKL).
*P values mark associations that remained significant after correction for multiple testing (clinical and genetic variants comparisons combined) by the Benjamini and Yekutieli 36 false discovery rate method (P≤0.014). December 2014
Rule Deduction and Patient Classification Using PART
Using PART, rules of lower complexity with a maximum of 10 variables were generated, which could be applied to a sufficient number of patients with adequate accuracy and transparency. The method of rule induction generates a set of if(combined)-then rules that can be used to discover interesting patterns in the data set (knowledge extraction) or, as a classification rule, to predict the outcome of subjects. PART generated rules with ≤100% accuracy using each of the 5 classifiers Clinical, Genotypes, Alleles, Clinical and Genotypes, and Clinical and Alleles. Although these rules were generated for computational classification of CRT patients and may be too complex for an individual straightforward analysis, an interpretation of some rules with low complexity is tempting. The rule [sex=F AND Age≤63] classified 15 of 16 patients correctly (93.75% accuracy) as RR+, which translates into the finding that younger female patients respond well to CRT, consistently with common clinical observations. Lack of type 2 diabetes mellitus was no classifier of high accuracy in our model even when combined with other clinical parameters (<91.7% accuracy).
In combination with the allele information on rs5443, the rule [diabetes mellitus=No AND rs5443=T AND LVEDV>197] exceeded 96% accuracy, pointing toward a protective role of the GNB3 rs5443 T allele in this setting. Female sex and the minor T allele of GNB3 rs5443 were also associated with CRT success by multivariable logistic regression analysis.
Study Limitations
The population studied in this investigation, although phenotypically well characterized, was retrospectively enrolled, consequently timing of follow-up echocardiography to define RR was not fixed but ranged from 6 to 12 months. Variability in timing of echocardiographic assessment is widely accepted in clinical trials of CRT, where a range of 45 days around the scheduled follow-up is generally used, and is probably unavoidable in real world designs such as in our study. However, although RR is known to occur even later than the first year, 13 longer follow-up is also likely to include intercurrent events unrelated to pump failure that may halt or invert an established favorable remodeling. Therefore, the median distance of 9 months observed in our series represents an appropriate time point. The study was relatively small and potentially not adequately powered to detect all genotype/ phenotype interactions, and not all genetic variants potentially associated with RR status after CRT have been included in the analysis. All our patients were whites, so genetic findings might not be extendable to other races. As the data set was relatively small, the results obtained by multivariable logistic regression analysis may be of limited accuracy. The current study should therefore be considered as a pilot study that could be the basis for a larger and prospective study.
Although the sample was balanced across many clinical confounders, additional parameters may be missing in the investigation. In particular, the groups were not matched for QRS morphology, an important predictor of CRT response, alone and in conjunction with a QRS duration ≥150 ms. 17, 18, 49 However, <10% of our patients had neither LBB nor a QRS duration ≥150 ms. Furthermore, QRS width did not differ by RR phenotype. The current models may present some features of so called model overtraining. This effect is mainly marked by accuracy values approximating 100% and results from data overfitting. Testing sensitivity and specificity in an additional and independent data set will be needed to prove broad practicability of the model. The model might perform less accurate when used on a data set containing specific records that were not included in the original data set.
Conclusion
Our data mining approach has identified combinations of different factors including genetic variants with impact on HF treatment outcomes, pointing to so far unknown underlying biological mechanisms. These findings underscore that an effective and efficient model for HF has to be based on a multiparameter model, including numerous known potential modifiers, to meet the needs for the high complexity of the disease. As any treatment of disease has certain risks and costs, there will always be treatment risk thresholds. 50 Current clinical decision making in HF patients is based on wellestablished conventional measures, and treatment is recommended if the individual risk is acceptable, even if treatment success is not fully predictable. Our study on CRT response in HF patients may help to guide appropriate therapy and improve clinical outcomes, at least in otherwise uncertain cases because it provides additional individual risk information. Selected rules based on different classifiers using the PART algorithm. Only rules with accuracy ≥80% are given. AF indicates atrial fibrillation; IDC, idiopathic dilated cardiomyopathy; IHD, ischemic heart disease; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; RR, reverse remodeling; VA, ventricular arrhythmias; and VALV, valvular defect.
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